The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study

References

• Song J, Jin C, Shan Z, Teng W, Li J. Prevalence and risk factors of hyperuricemia and gout: a cross-sectional survey from 31 provinces in Mainland China. J Transl Intern Med. 2022;10(2):134–145. doi:10.2478/jtim-2022-0031
   PubMed Web of Science ®Google Scholar
• Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–325. doi:10.1002/art.20405
   PubMed Web of Science ®Google Scholar
• Singh JA, Bharat A, Khanna D, et al. Health care utilization in patients with gout: a prospective multicenter cohort study. BMC Musculoskelet Disord. 2017;18(1):233. doi:10.1186/s12891-017-1573-6
   PubMedGoogle Scholar
• Uhlig T, Karoliussen LF, Sexton J, et al. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study. Arthritis Res Ther. 2022;24(1):88. doi:10.1186/s13075-022-02772-3
   PubMed Web of Science ®Google Scholar
• Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp. 2013;75:1–4. doi:10.1016/j.curtheres.2013.04.003
   PubMedGoogle Scholar
• Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA. 2022;328(5):440–450. doi:10.1001/jama.2022.11390
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tamaki S, Ide Y, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2):270–276. doi:10.1136/annrheumdis-2017-211574
   PubMed Web of Science ®Google Scholar
• Uhlig T, Karoliussen LF, Sexton J, et al. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study. Clin Rheumatol. 2022;41(12):3817–3823. doi:10.1007/s10067-022-06416-4
   PubMed Web of Science ®Google Scholar
• Mandell BF, Fields TR, Edwards NL, Yeo AE, Lipsky PE. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares. Clin Exp Rheumatol. 2021;39(5):1085–1092. doi:10.55563/clinexprheumatol/b7jjnb
   PubMed Web of Science ®Google Scholar
• Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789–1798. doi:10.1136/annrheumdis-2015-208237
   PubMed Web of Science ®Google Scholar
• Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a Phase III, international safety study. J Rheumatol. 2014;41(8):1703–1711. doi:10.3899/jrheum.131226
   PubMed Web of Science ®Google Scholar
• Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592–1600. doi:10.1136/annrheumdis-2019-215933
   PubMed Web of Science ®Google Scholar
• Liu J. Highlights of the 2018 Chinese hypertension guidelines. Clin Hypertens. 2020;26(1):8. doi:10.1186/s40885-020-00141-3
   PubMedGoogle Scholar
• American Diabetes Association. Standards of medical care in diabetes-2018 abridged for primary care providers. Clin Diabetes. 2018;36(1):14–37. doi:10.2337/cd17-0119
   PubMedGoogle Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK. Serum uric acid and the risk of incident and recurrent gout: a systematic review. J Rheumatol. 2017;44(3):388–396. doi:10.3899/jrheum.160452
   PubMed Web of Science ®Google Scholar
• Topless R, Noorbaloochi S, Merriman TR, Singh JA. Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout. Semin Arthritis Rheum. 2022;56:152057. doi:10.1016/j.semarthrit.2022.152057
   PubMed Web of Science ®Google Scholar
• Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):585–591. doi:10.1080/15257770802136032
   PubMed Web of Science ®Google Scholar
• Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–241. doi:10.1038/nature04516
   PubMed Web of Science ®Google Scholar
• Shiozawa A, Buysman EK, Korrer S. Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. Curr Med Res Opin. 2017;33(1):117–124. doi:10.1080/03007995.2016.1239193
   PubMed Web of Science ®Google Scholar
• Abhishek A, Valdes AM, Zhang W, Doherty M. Association of serum uric acid and disease duration with frequent gout attacks: a case-control study. Arthritis Care Res. 2016;68(10):1573–1577. doi:10.1002/acr.22855
   PubMed Web of Science ®Google Scholar
• Liang J, Jiang Y, Huang Y, et al. Comorbidities and factors influencing frequent gout attacks in patients with gout: a cross-sectional study. Clin Rheumatol. 2021;40(7):2873–2880. doi:10.1007/s10067-021-05595-w
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018;77(7):1048–1052. doi:10.1136/annrheumdis-2017-212288
   PubMed Web of Science ®Google Scholar
• Koide H, Hira D, Tsujimoto M, et al. Previous dosage of allopurinol is a strong determinant of febuxostat efficacy. Biol Pharm Bull. 2017;40(5):681–686.
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148(4):635–640. doi:10.1016/j.ahj.2004.04.005
   PubMed Web of Science ®Google Scholar
• Chino Y, Kuwabara M, Hisatome I. Factors influencing change in serum uric acid after administration of the sodium-glucose cotransporter 2 inhibitor luseogliflozin in patients with type 2 diabetes mellitus. J Clin Pharmacol. 2022;62(3):366–375. doi:10.1002/jcph.1970
   PubMed Web of Science ®Google Scholar
• Wu X, Li C. Fresh perspectives on the CARES trial and the use of febuxostat in an asian population: comment on the Article by Choi et al. Arthritis Rheumatol. 2019;71(3):479–481. doi:10.1002/art.40741
   PubMed Web of Science ®Google Scholar